Sponsor

Mario Negri Institute for Pharmacological Research

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Mario Negri Institute for Pharmacological Research appears in 47 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials47
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

47 shown
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC RegimenNCT06680050 · lead sponsor · 2025-08-07
RECRUITING
Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab DeruxtecanNCT07828054 · lead sponsor · 2026-12-20
NOT_YET_RECRUITING
Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and AbemaciclibNCT07428018 · lead sponsor · 2026-04-30
NOT_YET_RECRUITING
Mechanisms Underlying SGLT2i Kidney Effect in DKD ProgressionNCT07270198 · lead sponsor · 2026-02-01
NOT_YET_RECRUITING
MuLtidimensional School-based and Family interVentions to Promote hEalthy and Sustainable LifestYle for the ChildhoodNCT05966051 · lead sponsor · 2023-10-18
COMPLETED
Reduction Of Dietary Salt Intake To Control Systolic Blood Pressure In Hypertensive Older PatientsNCT05976477 · lead sponsor · 2023-10-01
UNKNOWN
LSCI and Thermography in Diabetic Foot Patients Affected by Ulcer(s): (MY-FOOT-B)NCT05791929 · lead sponsor · 2023-04-13
WITHDRAWN
A Prevention Trial of Canakinumab in Subjects at High Risk for Lung CancerNCT05725343 · lead sponsor · 2022-02-03
TERMINATED
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLCNCT04765709 · lead sponsor · 2021-09-24
TERMINATED
SGLT2 Inhibitors in Glomerular HyperfiltrationNCT04143581 · lead sponsor · 2021-09-03
WITHDRAWN
Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast CancerNCT04113863 · lead sponsor · 2019-06-18
TERMINATED
Insulin Treatment in Diabetic Older People With Heart Failure.NCT03665350 · lead sponsor · 2018-11-08
TERMINATED
Diadem to Investigate the Activity and Safety of DurvalumabNCT04115111 · lead sponsor · 2018-10-17
COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast CancerNCT03358017 · lead sponsor · 2018-03-05
COMPLETED
Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGationNCT03100253 · lead sponsor · 2018-03-01
TERMINATED
NEPHSTROM for Diabetic Kidney DiseaseNCT02585622 · lead sponsor · 2017-12-11
TERMINATED
CoQun Study - (COQUN): a Study to Evaluate the Effects of CoQun in Patients Affected by Open-angle GlaucomaNCT03611530 · lead sponsor · 2017-09-04
TERMINATED
Decision-aid on Breast Cancer ScreeningNCT03097653 · lead sponsor · 2017-09-01
COMPLETED
the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line TreatmentNCT03358004 · lead sponsor · 2017-06-14
TERMINATED
Pre-operative Zoledronate in Triple Negative Breast CancerNCT02347163 · lead sponsor · 2015-02-03
TERMINATED
ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)NCT02194231 · lead sponsor · 2013-07-01
COMPLETED
Effects of Caloric Restriction in Obesity and Type 2 DiabetesNCT01930136 · lead sponsor · 2013-05-01
COMPLETED
Multicentric Observational Study on Quality of Life in GlaucomaNCT01742104 · lead sponsor · 2012-03-01
COMPLETED
Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 DiabetesNCT01393808 · lead sponsor · 2011-09-01
COMPLETED
Tolvaptan for In-hospital HyponatremiaNCT01386372 · lead sponsor · 2011-06-01
TERMINATED
Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung CancerNCT01379976 · lead sponsor · 2011-04-01
TERMINATED
Preventing Renal Functional Abnormalities With Calorie Restriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular RiskNCT01213212 · lead sponsor · 2009-09-01
COMPLETED
Angiotensin-converting-enzyme (ACE) Inhibitors in HemodialysisNCT00985322 · lead sponsor · 2009-05-01
COMPLETED
Acetyl-L-Carnitine in Type 2 DiabetesNCT00984750 · lead sponsor · 2008-04-01
COMPLETED
Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of SchizophreniaNCT01052389 · lead sponsor · 2007-07-01
COMPLETED
Preventing Microalbuminuria in Type 2 DiabetesNCT00503152 · lead sponsor · 2007-05-01
COMPLETED
Preventing ESRD in Overt Nephropathy of Type 2 DiabetesNCT00494715 · lead sponsor · 2007-05-01
COMPLETED
Ezetimibe and Simvastatin in Dyslipidemia of DiabetesNCT00157482 · lead sponsor · 2005-01-01
COMPLETED
Acetylcarnitine and Insulin SensitivityNCT00393770 · lead sponsor · 2004-02-01
COMPLETED
Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular RiskNCT00317707 · lead sponsor · 2004-02-01
COMPLETED
Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early NephropathyNCT00157508 · lead sponsor · 2003-03-01
TERMINATED
Statins in Proteinuric NephropathiesNCT00199927 · lead sponsor · 2003-03-01
COMPLETED
L-Arginine in Pre-EclampsiaNCT00157521 · lead sponsor · 2002-09-01
COMPLETED
Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)NCT00157586 · lead sponsor · 2002-02-01
COMPLETED
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With ColchicineNCT06158698 · collaborator · 2023-11-14
RECRUITING
Health Effects of Secondhand Smoke Exposure in Outdoor Smoking Areas in Patients With COPD and Asthma ( TackSHSWP5 )NCT03074734 · collaborator · 2016-06-01
COMPLETED
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin TreatmentNCT02864030 · collaborator · 2014-05-01
COMPLETED
The Efficacy and Safety of Electronic Cigarettes: a 5-year Follow-up StudyNCT01785537 · collaborator · 2013-10-01
UNKNOWN
A Longitudinal Multidimensional Population Study on Brain AgingNCT01345110 · collaborator · 2009-11-01
COMPLETED
Tarceva Italian Lung Optimization tRialNCT00637910 · collaborator · 2007-11-01
UNKNOWN
Trastuzumab Optimization Trial in Breast CancerNCT00637325 · collaborator · 2007-11-01
UNKNOWN
The Effects of Bindarit in Diabetic NephropathyNCT01109212 · collaborator · 2007-03-01
COMPLETED

Drugs studied in this sponsor's trials

33 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Mario Negri Institute for Pharmacological Research as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo4
benazepril2
valsartan2
abemaciclib1
acetylcarnitine1
adalimumab1
arginine1
aripiprazole1
placebo RxCUI 8375 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 4 trials benazepril RxCUI 18867 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials valsartan RxCUI 69749 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials abemaciclib RxCUI 1946825 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial acetylcarnitine RxCUI 193 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial adalimumab RxCUI 327361 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial arginine RxCUI 1091 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial aripiprazole RxCUI 89013 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial canakinumab RxCUI 853491 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial capecitabine 500 MG RxCUI 315558 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial certolizumab pegol RxCUI 709271 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial colchicine RxCUI 2683 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial dexamethasone RxCUI 3264 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial durvalumab RxCUI 1919503 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial empagliflozin 10 MG RxCUI 1545654 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial eribulin mesylate RxCUI 1045452 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial erlotinib RxCUI 337525 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial etanercept RxCUI 214555 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ezetimibe RxCUI 341248 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fluvastatin RxCUI 41127 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial golimumab RxCUI 819300 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial haloperidol RxCUI 5093 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial infliximab RxCUI 191831 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor39
collaborator8
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.